The Behavioral Neurogenetics Center, The Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel Hashomer, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, PA, USA; Department of Child and Adolescent Psychiatry, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Schizophr Res. 2017 Oct;188:42-49. doi: 10.1016/j.schres.2016.12.023. Epub 2016 Dec 29.
About one third of individuals with 22q11.2 deletion syndrome (22q11.2DS) develop schizophrenia. Notably, a full-blown psychotic disorder is usually preceded by subthreshold symptoms. Therefore, it is important to identify early signs of psychosis in this population, a task that is complicated by the intellectual disabilities typically seen in 22q11.2DS. We aimed to identify subthreshold psychotic symptoms that distinguish 22q11.2DS from other neurodevelopmental disorders. The study included two independent cohorts from Tel Aviv and Philadelphia. 22q11.2DS (N=171) and typically developing (TD; N=832) individuals were enrolled at both sites and further compared to two groups with intellectual disabilities: Williams syndrome (WS; N=21) in the Tel Aviv cohort and idiopathic developmental disabilities (IDD; N=129) in the Philadelphia cohort. Participants and their primary caregivers were interviewed with the Structured Interview for Prodromal Symptoms (SIPS) and psychopathologies were assessed using standardized tools; general cognitive abilities were assessed with the Computerized Neurocognitive Battery. Negative/disorganized subthreshold syndrome was significantly more common in the 22q11.2DS group than in the WS (OR=3.90, 95% CI=1.34-11.34) or IDD (OR=5.05, 95% CI=3.01-10.08) groups. The 22q11.2DS group had higher scores than the two intellectual disabilities groups on several SIPS negative items, including avolition and decreased expression of emotion. Overall, there were few significant correlations between level of cognitive deficits and severity of negative symptoms in 22q11.2DS and only in the Tel Aviv cohort. Our findings suggest that 22q11.2DS individuals at the age of risk for developing psychosis should be closely monitored for negative symptoms.
大约三分之一的 22q11.2 缺失综合征(22q11.2DS)患者会发展为精神分裂症。值得注意的是,全面的精神病障碍通常是由亚临床症状引起的。因此,在该人群中识别精神病的早期迹象非常重要,但 22q11.2DS 通常存在智力障碍,这使得这项任务变得复杂。我们旨在确定区分 22q11.2DS 与其他神经发育障碍的亚临床精神病症状。该研究包括来自特拉维夫和费城的两个独立队列。在两个地点招募了 22q11.2DS(N=171)和典型发育(TD;N=832)个体,并与两个智力障碍组进行了进一步比较:特拉维夫队列中的威廉姆斯综合征(WS;N=21)和费城队列中的特发性发育障碍(IDD;N=129)。参与者及其主要照顾者接受了前驱症状结构化访谈(SIPS),并使用标准化工具评估了精神病理学;使用计算机神经认知电池评估了一般认知能力。与 WS(OR=3.90,95%CI=1.34-11.34)或 IDD(OR=5.05,95%CI=3.01-10.08)组相比,22q11.2DS 组的阴性/紊乱前驱综合征更为常见。与两个智力障碍组相比,22q11.2DS 组在几个 SIPS 阴性项目上的得分更高,包括意志减退和情绪表达减少。总体而言,在 22q11.2DS 中,认知缺陷的严重程度与阴性症状之间只有在特拉维夫队列中才存在少量显著相关性。我们的研究结果表明,处于发展精神病风险的 22q11.2DS 个体应密切监测其阴性症状。